Logo image of MRUS

MERUS NV (MRUS) Stock Overview

USA - NASDAQ:MRUS - NL0011606264 - Common Stock

94.83 USD
-0.02 (-0.02%)
Last: 10/14/2025, 4:08:06 PM
94.95 USD
+0.12 (+0.13%)
After Hours: 10/14/2025, 4:08:06 PM

MRUS Key Statistics, Chart & Performance

Key Statistics
52 Week High95.02
52 Week Low33.19
Market Cap7.19B
Shares75.78M
Float73.18M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-5.54
PEN/A
Fwd PEN/A
Earnings (Next)10-30 2025-10-30/amc
IPO05-19 2016-05-19
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


MRUS short term performance overview.The bars show the price performance of MRUS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80 100

MRUS long term performance overview.The bars show the price performance of MRUS in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of MRUS is 94.83 USD. In the past month the price increased by 39.3%. In the past year, price increased by 80.02%.

MERUS NV / MRUS Daily stock chart

MRUS Latest News, Press Relases and Analysis

MRUS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.64 404.77B
AMGN AMGEN INC 13.47 158.20B
GILD GILEAD SCIENCES INC 15.31 147.01B
VRTX VERTEX PHARMACEUTICALS INC 24.33 105.69B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 61.52B
REGN REGENERON PHARMACEUTICALS 12.55 60.69B
ARGX ARGENX SE - ADR 87.7 49.75B
ONC BEONE MEDICINES LTD-ADR 5.19 35.25B
INSM INSMED INC N/A 34.11B
BNTX BIONTECH SE-ADR N/A 24.67B
NTRA NATERA INC N/A 23.72B
BIIB BIOGEN INC 9.08 21.30B

About MRUS

Company Profile

MRUS logo image Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 260 full-time employees. The company went IPO on 2016-05-19. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The firm operates in the Netherlands and United States.

Company Info

MERUS NV

Yalelaan 62

Utrecht UTRECHT 3584 NL

CEO: Sven A. Lundberg

Employees: 291

MRUS Company Website

MRUS Investor Relations

Phone: 310302538800

MERUS NV / MRUS FAQ

What is the stock price of MERUS NV today?

The current stock price of MRUS is 94.83 USD. The price decreased by -0.02% in the last trading session.


What is the ticker symbol for MERUS NV stock?

The exchange symbol of MERUS NV is MRUS and it is listed on the Nasdaq exchange.


On which exchange is MRUS stock listed?

MRUS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MERUS NV stock?

23 analysts have analysed MRUS and the average price target is 94.52 USD. This implies a price decrease of -0.33% is expected in the next year compared to the current price of 94.83. Check the MERUS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MERUS NV worth?

MERUS NV (MRUS) has a market capitalization of 7.19B USD. This makes MRUS a Mid Cap stock.


How many employees does MERUS NV have?

MERUS NV (MRUS) currently has 291 employees.


What are the support and resistance levels for MERUS NV (MRUS) stock?

MERUS NV (MRUS) has a support level at 94.84 and a resistance level at 94.86. Check the full technical report for a detailed analysis of MRUS support and resistance levels.


Is MERUS NV (MRUS) expected to grow?

The Revenue of MERUS NV (MRUS) is expected to grow by 35.25% in the next year. Check the estimates tab for more information on the MRUS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MERUS NV (MRUS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MERUS NV (MRUS) stock pay dividends?

MRUS does not pay a dividend.


When does MERUS NV (MRUS) report earnings?

MERUS NV (MRUS) will report earnings on 2025-10-30, after the market close.


What is the Price/Earnings (PE) ratio of MERUS NV (MRUS)?

MERUS NV (MRUS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.54).


What is the Short Interest ratio of MERUS NV (MRUS) stock?

The outstanding short interest for MERUS NV (MRUS) is 5.92% of its float. Check the ownership tab for more information on the MRUS short interest.


MRUS Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to MRUS. When comparing the yearly performance of all stocks, MRUS is one of the better performing stocks in the market, outperforming 93.73% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MRUS Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to MRUS. MRUS has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MRUS Financial Highlights

Over the last trailing twelve months MRUS reported a non-GAAP Earnings per Share(EPS) of -5.54. The EPS decreased by -93.03% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -39.33%
ROE -45.8%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-175.31%
Sales Q2Q%20.4%
EPS 1Y (TTM)-93.03%
Revenue 1Y (TTM)59.78%

MRUS Forecast & Estimates

23 analysts have analysed MRUS and the average price target is 94.52 USD. This implies a price decrease of -0.33% is expected in the next year compared to the current price of 94.83.

For the next year, analysts expect an EPS growth of -84.27% and a revenue growth 35.25% for MRUS


Analysts
Analysts72.17
Price Target94.52 (-0.33%)
EPS Next Y-84.27%
Revenue Next Year35.25%

MRUS Ownership

Ownership
Inst Owners101.95%
Ins Owners0.37%
Short Float %5.92%
Short Ratio3.16